Treatment of lupus nephritis

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 901-911

  Dolff, Sebastian ^a,b   Berden, Jo Hm ^c   Bijl, Marc ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

glomerulonephritis; lupus nephritis; SLE; treatment

Indexed keywords

ABATACEPT; ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BELIMUMAB; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; EPRATUZUMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; TACROLIMUS;

AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE DRUG DOSE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MENINGITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; OSTEOPOROSIS; PNEUMONIA; PREVENTIVE MEDICINE; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL CLASSIFICATION OF DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PRACTICE GUIDELINES AS TOPIC;

EID: 78049435817     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.79     Document Type: Review

References (76)

1. Hahn BH. Antibodies to DNA. N. Engl. J. Med. 338(19), 1359-1368 (1998).
2. Doria A, Iaccarino L, Ghirardello A et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am. J. Med. 119(8), 700-706 (2006).
3. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. Q. J. Med. 92(4), 211-218 (1999).
4. Berden JH. Lupus nephritis. Kidney Int. 52(2), 538-558 (1997).
5. Winfeld JB, Faiferman I, Koffer D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J. Clin. Invest. 59(1), 90-96 (1977).
6. Pankewycz OG, Migliorini P, Madaio MP. Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J. Immunol. 139(10), 3287-3294 (1987).
7. van Bruggen MC, Kramers C, Hylkema MN, Smeenk RJ, Berden JH. Signifcance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice. Clin. Exp. Immunol. 105(1), 132-139 (1996).
8. Faaber P, Rijke TP, van de Putte LB, Capel PJ, Berden JH. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J. Clin. Invest. 77(6), 1824-1830 (1986).
9. van Bavel CC, Fenton KA, Rekvig OP, van der Vlag J, Berden JH. Glomerular targets of nephritogenic autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 58(7), 1892-1899 (2008).
10. Nagafuchi H, Shimoyama Y, Kashiwakura J, Takeno M, Sakane T, Suzuki N. Preferential expression of B72 (CD86), but not B71 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 21(1), 71-77 (2003).
11. Bijl M, Horst G, Limburg PC, Kallenberg CG. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 60(5), 523-526 (2001). (Pubitemid 32417429)
12. + T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 145(2), 235-242 (2006).
13. + T cells are enriched in infamed kidneys and urine and provide a new biomarker for acute nephritis fares in systemic lupus erythematosus patients. Arthritis Rheum. 60(1), 199-206 (2009).
14. Dolff S, Abdulahad WH, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M. Urinary T cells in active lupus nephritis show an effector memory phenotype. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.124636 (2010) (Epub ahead of print).
15. Houssiau FA, D'Cruz D, Vianna J, Hughes GR. Lupus nephritis: the signifcance of serological tests at the time of biopsy. Clin. Exp. Rheumatol. 9(4), 345-349 (1991).
16. Hill GS, Hinglais N, Tron F, Bach JF. Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am. J. Med. 64(1), 61-79 (1978).
17. Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q. J. Med. 72(269), 779-833 (1989).
18. Weening JJ, DAgati VD, Schwartz MM et al. The classifcation of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65(2), 521-530 (2004).
19. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identifcation of specifc pathologic features affecting renal outcome. Kidney Int. 25(4), 689-695 (1984).
20. Austin HA, III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 45(2), 544-550 (1994).
21. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical effcacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69(1), 20-28 (2010).
22. Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol. Dial. Transplant. 21(6), 1465-1469 (2006).
23. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only Arthritis Rheum. 34(8), 945-950 (1991).
24. Gourley MF, Austin HA III, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 125(7), 549-557 (1996).
25. Boumpas DT, Austin HA III, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340(8822), 741-745 (1992).
26. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46(8), 2121-2131 (2002).
27. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69(1), 61-64 (2010).
28. Grootscholten C, Ligtenberg G, Hagen EC et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70(4), 732-742 (2006).
29. Grootscholten C, Bajema IM, Florquin S et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum. 56(3), 924-937 (2007).
30. Chan TM, Li FK, Tang CS et al. Effcacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343(16), 1156-1162 (2000).
31. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16(4), 1076-1084 (2005).
32. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353(21), 2219-2228 (2005).
33. Appel GB, Contreras G, Dooley MA et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20(5), 1103-1112 (2009).
34. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multi target therapy. J. Am. Soc. Nephrol. 19(10), 2001-2010 (2008).
35. Isenberg D, Appel GB, Contreras G et al. Infuence of race/ethnicity on response to lupus nephritis treatment: the ALMS study Rheumatology (Oxford) 49(1), 128-140 (2010).
36. Moroni G, Doria A, Mosca M et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol. 1(5), 925-932 (2006).
37. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350(10), 971-980 (2004).
38. Houssiau FA, D'Cruz DP, Sangle SR. Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: results of a randomized trial (MAINTAIN); Presented at: 73rd Annual Scientifc Meeting of the American College of Rheumatology. Philadelphia, PA, USA, 19 October 2009.
39. Zhu B, Chen N, Lin Y et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol. Dial. Transplant. 22(7), 1933-1942 (2007).
40. Bhinder S, Singh A, Majithia V. Membranous (class V) renal disease in systemic lupus erythematosus may be more common than previously reported: results of a 6-year retrospective analysis. Am. J. Med. Sci. 339(3), 230-232 (2010).
41. Moroni G, Maccario M, Banf G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am. J. Kidney Dis. 31(4), 681-686 (1998).
42. Radhakrishnan J, Kunis CL, DAgati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy Clin. Nephrol. 42(3), 147-154 (1994).
43. Mercadal L, Montcel ST, Nochy D et al. Factors affecting outcome and prognosis in membranous lupus nephropathy Nephrol. Dial. Transplant. 17(10), 1771-1778 (2002).
44. Austin HA III, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20(4), 901-911 (2009).
45. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 77(2), 152-160 (2010).
46. Mok CC, Ying KY, Yim CW, Ng WL, Wong WS. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus 18(12), 1091-1095 (2009).
47. Rietveld A, Berden JH. Renal replacement therapy in lupus nephritis. Nephrol. Dial. Transplant. 23(10), 3056-3060 (2008).
48. Masood S, Jayne D, Karim Y Beyond immunosuppression-challenges in the clinical management of lupus nephritis. Lupus 18(2), 106-115 (2009).
49. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15(10), 675-682 (2006).
50. de Leeuw K, Smit AJ, de Groot E, van Roon AM, Kallenberg CG, Bijl M. Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis 206(2), 546-550 (2009).
51. Duran-Barragan S, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 47(7), 1093-1096 (2008).
52. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68(2), 238-241 (2009).
53. Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int. 73(3), 261-268 (2008).
54. Emery P, Deodhar A, Rigby WF et al. Effcacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximabs Effcacy in MTX iNadequate rEsponders [SERENE]). Ann. Rheum. Dis. 69(9), 1629-1635 (2010).
55. Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and effcacy of retreatment. Ann. Rheum. Dis. 68(2), 284-285 (2009).
56. Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin. Rev. Allergy Immunol. (2010) (Epub ahead of print).
57. Furie R, Looney RJ, Rovin B. Effcacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind Phase III LUNAR study Presented at: 73rd Annual Scientifc Meeting of the American College of Rheumatology. Philadelphia, PA, USA, 19 October 2009.
58. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8(3), R74 (2006).
59. Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58(4), 953-963 (2008).
60. Dolff S, Wilde B, Patschan S et al. Peripheral circulating activated B-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus. Scand. J. Immunol. 66(5), 584-590 (2007).
61. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166(5), 2913-2916 (2001).
62. Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J. Am. Soc. Nephrol. 11(8), 1426-1438 (2000).
63. Zhou YB, Ye RG, Li YJ, Xie CM. Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis. Rheumatol. Int. 29(4), 417-425 (2009).
64. Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48(3), 719-727 (2003).
65. Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J. Rheumatol. 24(2), 314-318 (1997).
66. Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28(2), 257-265 (2001).
67. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal fare in systemic lupus erythematosus: results of a randomized, controlled Phase III trial. Arthritis Rheum. 58(8), 2470-2480 (2008).
68. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781), 995-999 (2000).
69. Wallace DJ, Stohl W, Furie RA et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61(9), 1168-1178 (2009).
70. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56(4), 1263-1272 (2007).
71. Terrier B, Amoura Z, Ravaud P et al. Safety and effcacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry Arthritis Rheum. 62(8), 2458-2466 (2010).
72. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18(9), 767-776 (2009).
73. Ramos-Casals M, Diaz-Lagares C, Khamashta MA. Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum. 61(9), 1281-1282 (2009).
74. Alexander T, Thiel A, Rosen O et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113(1), 214-223 (2009).
75. Liang J, Zhang H, Hua B et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann. Rheum. Dis. 69(8), 1423-1429 (2010).
76. Sun L, Wang D, Liang J et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 62(8), 2467-2475 (2010).